DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 168

Registration Number: NCT00239395

Locations: 🇨🇳
People's Hospital, Beijing University, Beijing, China
🇨🇳
Shanghai Guanghai Hospital, Shanghai, China
🇨🇳
Beijing Xuan Wu Hospital, Beijing, China

and more 5 locations

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Phase 4

Completed

Conditions: Hypertension
Diabetes Mellitus, Type 2

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 840

Registration Number: NCT00239538

Locations: 🇺🇸
1200, Los Angeles, California, United States
🇺🇸
Attention: Larry I. Gilderman, D.O., Pembroke Pines, Florida, United States
🇺🇸
200, Baltimore, Maryland, United States

and more 30 locations

A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-10-17

Last Posted Date: 2012-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT00239434

Locations: 🇨🇳
Zhongshan Hospital of Fudan University, Shanghai, China
🇨🇳
People Hospital of Beijing University, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China

and more 3 locations

A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2005-10-17

Last Posted Date: 2018-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 150

Registration Number: NCT00239382

Locations: 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, China
🇨🇳
Shanghai Guanghai Hospital, Shanghai, China
🇨🇳
People's Hospital, Beijing University, Beijing, China

and more 5 locations

Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)

Phase 2

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 109

Registration Number: NCT00239486

Locations: 🇫🇮
NEURO, Helsinki, Finland

Tiotropium / Respimat One-Year Study

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium Inhalation Solution
Other: Placebo

First Posted Date: 2005-09-15

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 983

Registration Number: NCT00168844

Locations: 🇬🇧
Boehringer Ingelheim Investigational Site, Torquay, United Kingdom

Tiotropium / Respimat One-Year Study

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium Inhalation Solution
Other: Placebo

First Posted Date: 2005-09-15

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1007

Registration Number: NCT00168831

Locations: 🇦🇹
Baumgartner Hohe Otto Wagner Spital Wien, Wien, Austria
🇬🇧
Boehringer Ingelheim Investigational Site, Sunderland, United Kingdom

Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery

Phase 3

Completed

Conditions: Arthroplasty, Replacement, Hip
Thromboembolism

Interventions: Drug: dabigatran etexilate
Drug: enoxaparin

First Posted Date: 2005-09-15

Last Posted Date: 2014-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3494

Registration Number: NCT00168818

Locations: 🇦🇺
1160.48.06102 Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺
1160.48.06104 Ecru, Box Hill, Victoria, Australia
🇦🇺
1160.48.06110 Suite 13 level 4, Lismore, New South Wales, Australia

and more 113 locations

RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

Phase 3

Completed

Conditions: Arthroplasty, Replacement, Knee
Thromboembolism

Interventions: Drug: dabigatran etexilate
Drug: enoxaparin

First Posted Date: 2005-09-15

Last Posted Date: 2014-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2101

Registration Number: NCT00168805

Locations: 🇦🇺
1160.25.06103 Boehringer Ingelheim Investigational Site, Ringwood East, Victoria, Australia
🇦🇹
1160.25.04303 Boehringer Ingelheim Investigational Site, Wels, Austria
🇨🇿
1160.25.42010 Boehringer Ingelheim Investigational Site, Chomutov, Czech Republic

and more 102 locations

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2005-09-15

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1185

Registration Number: NCT00168779

Locations: 🇺🇸
502.476.064 Boehringer Ingelheim Investigational Site, Kettering, Ohio, United States
🇺🇸
502.476.003 Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States
🇺🇸
502.476.086 Boehringer Ingelheim Investigational Site, Encinitas, California, United States

and more 110 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy